PDCD1 and nonpapillary renal cell carcinoma: However, in a subsequent phase II study in advanced ccRCC after progression of PD-1/PD-L1 inhibition, axitinib with PF-04518600 did not improve clinical outcomes compared to axitinib alone (median PFS: 13.1 vs. 8.5 months, HR: 0.85, 95% CI: 0.45–1.60, p-value: 0.61) [86].